Physician profile
Megan E Eshbaugh
NPI 1710137096
$17,097.39
in general payments reported to CMS, 2019-2025
38 companies · $3,005 in 2025
The $3,005 reported for 2025 was more than what 77% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,902 · 2020: $1,547 · 2021: $1,797 · 2022: $2,081 · 2023: $2,795 · 2024: $2,971 · 2025: $3,005.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,699 · Education: $72.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,698.77 |
| Education | $72.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $3,721.32 | 2019-2025 | Enbrel, Otezla, Tavneos |
| Abbvie INC. | $2,306.51 | 2019-2025 | |
| Janssen Biotech, INC. | $1,504.34 | 2019-2025 | Tremfya, Stelara, Remicade |
| Pfizer INC. | $1,431.27 | 2019-2025 | |
| Ucb, INC. | $1,208.28 | 2019-2025 | Cimzia, Bimzelx |
| Novartis Pharmaceuticals Corporation | $1,094.84 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $912.71 | 2019-2025 | Orencia |
| Radius Health, INC. | $780.58 | 2019-2025 | Tymlos |
| Glaxosmithkline, LLC. | $532.30 | 2019-2025 | Benlysta |
| Astrazeneca Pharmaceuticals Lp | $475.78 | 2021-2025 | Saphnelo |
| Lilly USA, LLC | $454.02 | 2019-2024 | Taltz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $419.03 | 2021-2025 | Ofev, Cyltezo |
| Celgene Corporation | $304.16 | 2019-2024 | Orencia |
| Genentech USA, INC. | $232.28 | 2019-2025 | Actemra |
| Mallinckrodt Hospital Products INC. | $206.94 | 2021-2025 | Acthar |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Megan Eshbaugh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.